(Q33785083)

29 July 2017

title

Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy (English)

1 reference

29 July 2017

0 references

Yves Poulin

1

1 reference

29 July 2017

Pranav Sheth

series ordinal

2

1 reference

29 July 2017

Yihua Gu

series ordinal

3

1 reference

29 July 2017

Henrique D Teixeira

series ordinal

4

1 reference

29 July 2017

publication date

1 February 2014

1 reference

29 July 2017

published in

Dermatology and therapy

1 reference

29 July 2017

volume

4

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

33-42

1 reference

Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Application of the dermatology life quality index in clinical trials of biologics for psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

4 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13555-014-0043-4

Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065279

Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24488828

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13555-014-0043-4

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference